Screening Libraries and Drug Repurposing

The traditional drug development model, requiring chemical development, pre-clinical investigation of mechanism of action and safety, and multiple rounds of human clinical trials, can take many years from discovery to a treatment being made available to patients. To expedite the drug discovery process researchers can turn to approved drugs and take advantage of their regulatory approval for other indications. This process is known as drug repurposing or drug repositioning.

Research Areas

Screening Libraries and Drug Repurposing Product Areas

COVID-19 Bioactive Compound Library

The COVID-19 Bioactive Compound Library, available through the Tocriscreen PRO Custom Compound Library service, is composed of a subset of products from the Tocriscreen 2.0 Compound Library. Compounds within this collection target key proteins within the SARS-CoV-2 viral life cycle or have been linked to Coronaviruses and COVID-19 within the scientific literature. This library is available in 10 mM DMSO solutions (50 μL - 1 mL) or as dry powder (2 - 10 mg).

Please complete the compound library inquiry form to inquire about this library.

Drug repurposing for COVID-19

Repurposing or repositioning of approved drugs for COVID-19 enables researchers to shorten the research and development cycle. Both recently approved drugs and established therapeutics have been identified as potential treatments for COVID19:

Dexamethasone (Cat. No. 1126) was initially approved for medical use in 1961 and is an anti-inflammatory glucocorticoid, also known as a steroid. It is approved for the treatment of many inflammatory and autoimmune conditions, such as rheumatoid arthritis. It is also used as a chemotherapeutic agent in various cancers of the blood.

Lopinavir (Cat. No. 7052) was approved for medical use in 2000 and is a retroviral protease inhibitor used to treat HIV infections, in combination with ritonavir (Cat. No. 5856). Lopinavir inhibits HIV-1 protease, and has also been shown to inhibit HPV, MERS-CoV and SARS-CoV-2 viral infections in vitro.

Remdesivir (Cat. No. 7226) is a broad-spectrum antiviral that was initially developed as a treatment for Ebola in the mid-2010s. It is a viral RNA-dependent RNA polymerase inhibitor and nucleotide prodrug, which exhibits activity against a range of RNA viruses including EBOV, MERS-CoV and SARS-CoV-2.